Becton, Dickinson And Co. (BDX)
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A.
The Company's operations outside the United States include Europe; the Middle East and Africa (EMA); Greater Asia, which includes Japan and Asia Pacific; Latin America, which includes Mexico, Central America, the Caribbean and South America, and Canada. BD has manufacturing operations outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain and the United Kingdom. It sells its products under various brands, such as BD Hypak, Alaris, Pyxis and Vacutainer, BD Kiestra, BD Max, BD BACTEC, SurePath, Veritor, BD ProbeTec and BD Viper.
The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems.
The diabetes care unit includes various products lines, such as syringes, pen needles and intravenous (IV) sets for the injection or infusion of insulin and other drugs used in the treatment of diabetes. The medication and procedural solutions unit includes various product lines, such as needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products, and surgical and laproscopic instrumentation. The medication management solutions unit includes intravenous medication safety and infusion therapy delivery systems, such as infusion pumps and dedicated disposables; medication compounding workflow systems, and automated medication dispensing and supply management systems. The pharmaceutical systems unit includes prefillable drug delivery systems provided to pharmaceutical companies and sold to end users as drug/device combinations. The businesses served by BD Medical are hospitals and clinics, physicians' office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.
BD Life Sciences
The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. The BD Life Sciences segment produces research and clinical tools that facilitate the study of cells, the components of cells, and to gain an understanding of normal and disease processes. The BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences. The preanalytical systems unit includes integrated systems for specimen collection, and safety-engineered blood collection products and systems. The diagnostic systems unit includes automated blood culturing and tuberculosis culturing systems, molecular testing systems for infectious diseases and women's health, microorganism identification and drug susceptibility systems, liquid-based cytology systems for cervical cancer screening, rapid diagnostic assays, microbiology laboratory automation, and plated media. The biosciences unit includes fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, human immunodeficiency virus (HIV) and transplantation diagnostic/monitoring reagents and analyzers, and cell culture media supplements for biopharmaceutical manufacturing. The primary businesses served by BD Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians' office practices; academic and government institutions, and pharmaceutical and biotechnology companies.
- Pharmaceuticals & Biotechnology
- 🇺🇸 United States
- $258.73 yesterday's close
52 Week High1.88%03 September 2019
52 Week Low1.19%06 September 2019
Next Ex-Div-Date Countdown
|Ex-Div Date||Pay Date||Year||Type||Frequency||Status||Amount|
|07 Mar 2012||30 Mar 2012||2011||Final||Quarterly||Paid||45c|
|06 Jun 2012||29 Jun 2012||2012||Interim||Quarterly||Paid||45c|
|05 Sep 2012||28 Sep 2012||2012||Interim||Quarterly||Paid||45c|
|06 Dec 2012||31 Dec 2012||2012||Interim||Quarterly||Paid||49.5c|
|06 Mar 2013||29 Mar 2013||2012||Final||Quarterly||Paid||49.5c|
|05 Jun 2013||28 Jun 2013||2013||Interim||Quarterly||Paid||49.5c|
|05 Sep 2013||30 Sep 2013||2013||Final||Quarterly||Paid||49.5c|
|06 Dec 2013||31 Dec 2013||2014||Interim||Quarterly||Paid||54.5c|
|06 Mar 2014||31 Mar 2014||2014||Interim||Quarterly||Paid||54.5c|
|05 Jun 2014||30 Jun 2014||2014||Interim||Quarterly||Paid||54.5c|
|05 Sep 2014||30 Sep 2014||2014||Final||Quarterly||Paid||54.5c|
|08 Dec 2014||31 Dec 2014||2015||Interim||Quarterly||Paid||60c|
|06 Mar 2015||31 Mar 2015||2015||Interim||Quarterly||Paid||60c|
|05 Jun 2015||30 Jun 2015||2015||Interim||Quarterly||Paid||60c|
|04 Sep 2015||30 Sep 2015||2015||Final||Quarterly||Paid||60c|
|08 Dec 2015||31 Dec 2015||2016||Interim||Quarterly||Paid||66c|
|08 Mar 2016||31 Mar 2016||2016||Interim||Quarterly||Paid||66c|
|07 Jun 2016||30 Jun 2016||2016||Interim||Quarterly||Paid||66c|
|07 Sep 2016||30 Sep 2016||2016||Final||Quarterly||Paid||66c|
|07 Dec 2016||30 Dec 2016||2017||Interim||Quarterly||Paid||73c|
|08 Mar 2017||31 Mar 2017||2017||Interim||Quarterly||Paid||73c|
|07 Jun 2017||30 Jun 2017||2017||Interim||Quarterly||Paid||73c|
|07 Sep 2017||29 Sep 2017||2017||Final||Quarterly||Paid||73c|
|07 Dec 2017||29 Dec 2017||2018||Interim||Quarterly||Paid||75c|
|08 Mar 2018||30 Mar 2018||2018||Interim||Quarterly||Paid||75c|
|07 Jun 2018||29 Jun 2018||2018||Interim||Quarterly||Paid||75c|
|06 Sep 2018||28 Sep 2018||2018||Final||Quarterly||Paid||75c|
|07 Dec 2018||31 Dec 2018||2019||Interim||Quarterly||Paid||77c|
|07 Mar 2019||29 Mar 2019||2019||Interim||Quarterly||Paid||77c|
|06 Jun 2019||28 Jun 2019||2019||Interim||Quarterly||Paid||77c|
|06 Sep 2019||30 Sep 2019||2019||Final||Quarterly||Declared||77c|
Becton, Dickinson And Co. optimized dividend - 12 month history
Becton, Dickinson And Co. share price - 12 month history
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn: